Sign In
Buy NVTA
$0.0190
+0 (+0%)
At Close: May 13, 2024
NVTA Stock: Invitae Plunges 78% on the Brink of Bankruptcy
10:18am, Tuesday, 06'th Feb 2024
Invitae (NYSE: NVTA ) stock fell as much as 78% yesterday before it was ultimately halted because undisclosed news about the firm was pending. Many investors now expect that the SoftBank (OTCMKTS: SFT
Why Is Invitae (NVTA) Stock Down 75% Today?
02:26pm, Monday, 05'th Feb 2024
Medical genetics firm Invitae (NYSE: NVTA ) suffered a shocking fall from grace as insider reports point to an upcoming bankruptcy filing. Although the company forwarded a compelling concept — lever
Medical test maker Invitae prepares for bankruptcy - WSJ
11:46am, Monday, 05'th Feb 2024
Medical test maker Invitae is preparing to file for bankruptcy within weeks, the Wall Street Journal reported on Monday, according to people familiar with the matter.
Invitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare Disease Therapeutics
07:00am, Tuesday, 30'th Jan 2024
SAN FRANCISCO , Jan. 30, 2024 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced a partnership with BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage b
Is Invitae Stock a Buy Now?
04:46am, Monday, 29'th Jan 2024
Invitae has made progress in its business realignment plan, cutting cash burn by one-half from 2022 to 2023. However, the company still faces significant challenges.
Invitae Completes Sale of Reproductive Health Assets to Natera
07:00am, Monday, 22'nd Jan 2024
SAN FRANCISCO , Jan. 22, 2024 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced it has completed the sale of certain reproductive health assets, which incl
Natera Acquires Reproductive Health Assets from Invitae
07:00am, Monday, 22'nd Jan 2024
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced that it has acquired from Invitae (NYSE: NVTA), a leading medical genetic
Pick These Top-Ranked Stocks to Deck Up Your Christmas Tree
11:18am, Friday, 22'nd Dec 2023
We have crafted a tree with the most flourishing stocks of 2023 and the ones that are poised to soar in 2024.
Despite Fast-paced Momentum, Invitae (NVTA) Is Still a Bargain Stock
10:33am, Friday, 22'nd Dec 2023
Invitae (NVTA) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that ma
Why Are Chinese Stocks Up Today?
11:35am, Friday, 15'th Dec 2023
Chinese stocks are up today and investors wondering why can find out all about these movements with our coverage for Friday! All of this comes from recent data concerning the Chinese economy.
What Makes Invitae (NVTA) a New Buy Stock
01:32pm, Wednesday, 13'th Dec 2023
Invitae (NVTA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
3 Cathie Wood Stocks to Sell Before It's Too Late
07:00pm, Monday, 11'th Dec 2023
The allure of Cathie Wood Stocks investing prowess has captured a large audience of investors. Yet, even amidst all of the optimism surrounding her investment strategies, prudent investors must be awa
Better Growth Stock: CRISPR Therapeutics vs. Invitae
05:00am, Tuesday, 05'th Dec 2023
CRISPR Therapeutics may soon generate its first product revenue. Invitae, making progress in its recovery plan, could climb if it meets its goals.
Invitae Corporation (NVTA) Q3 2023 Earnings Call Transcript
09:22pm, Wednesday, 08'th Nov 2023
Invitae Corporation (NYSE:NVTA ) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Hoki Luk - VP, IR and Corporate Development Ken Knight - President & CEO Ana Schrank
Invitae (NVTA) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
07:32pm, Wednesday, 08'th Nov 2023
The headline numbers for Invitae (NVTA) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street esti
